Molnlycke Health Care AB
Molnlycke Health Care AB sponsors 20 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 15 completed. 4 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Wounds, with 2 trials.
Trial Pipeline
20 total, page 1 of 1
A Clinical Investigation to Follow the Progress of Exuding Chronic Venous Leg Ulcers Using a Non-Bordered Foam Dressing
NCT05608317
A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing.
NCT05588583
Interventional Study Exploring the Occurrence of Surgical Site Infections.
NCT06661473
Performance and Safety of Exufiber Ag+ and Exufiber on Partial Thickness Burns
NCT04839523
An Open, Non-comparative, Multicenter Investigation to Evaluate the Safety and Performance of Exufiber Ag+, a Gelling Fiber Silver Dressing, When Used in Medium to High Exuding Chronic Wounds
NCT05494450
Evaluation of the Residual Antimicrobial Efficacy of One Test Material Based on a Modification of ASTM E1115-11 Test Method
NCT04654182
Evaluation of Chlorhexidine Gluconate Concentration on Skin of Human Subjects Following Multiple Application Times
NCT04235985
Clinical Study to Compare 3 Multi-Layered Foam Dressings for the Management of Chronic Wounds
NCT03662997
Durability of Double-gloving With Biogel® Surgical Gloves When Used by Clinicians/Surgeons
NCT03344354
Evaluation of Exufiber Ag+ and Other Gelling Fibre Dressings
NCT03249909
Self-adherent Absorbent Silver Dressing in Adults After Hip or Knee Arthroplasty
NCT03016078
Pressure Injury Prevention in the ICU With Multi-Layer Foam Dressings
NCT02962882
A Soft Silicone Wound Contact Layer Containing Silver in the Treatment of Skin Grafts in Surgical Burn Patients.
NCT02210208
An Open Single-centre Investigation Evaluating Efficacy in Second Degree Partial Thickness Burns Using a Silicone Contact Layer Containing Silver.
NCT01734317
An Investigation to Evaluate a New Donor Site Dressing in Surgical Burn Patients
NCT01670201
A Clinical Investigation to Evaluate Efficacy of Mepitel Ag in Partial Thickness Second Degree Burns
NCT01636362
Clinical Utility of a New Silver Gel for Use on Chronic Wounds
NCT01442103
Open, Prosp, Rand. Invest. Evaluating Pain With Mepitel One vs.Bridal Veil and Staples on Split Thickness Skin Grafts
NCT01365273
Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing
NCT01214811
Evaluating the Cost-effectiveness, Efficacy, Safety and Tolerance of Mepilex® Ag Versus Silvadene®
NCT00742183
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
| Phase 4 | 3 |
Therapeutic Areas
What the Pipeline for Molnlycke Health Care AB Shows
According to the ClinicalTrials.gov registry, Molnlycke Health Care AB is linked to 20 US clinical trials across every stage of research activity. Of those, 2 studies are currently recruiting, about 10% of the sponsor's indexed portfolio, and 15 are already marked complete, representing roughly 75% of the total.
The phase mix for Molnlycke Health Care AB reports 4 late-stage studies (Phase 3 and Phase 4 combined) and 0 earlier-phase studies (Phase 1 and Phase 2).
The top therapeutic focus area indexed for Molnlycke Health Care AB is Wounds with 2 linked trials, and 9 other condition areas appear in the top list above.
How to read these pipeline numbers
Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.